Welcome to our dedicated page for Can-Fite BioPharma Ltd. SEC filings (Ticker: CANF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Can-Fite BioPharma Ltd. (CANF) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on the NYSE American. Can-Fite files an annual report on Form 20-F and frequent current reports on Form 6-K, which together describe its clinical programs, financial results, capital structure, and corporate actions. These filings are sourced in real time from the SEC’s EDGAR system and are organized for convenient review.
In its Form 6-K reports, Can-Fite often furnishes press releases covering developments such as clinical trial enrollment updates for Namodenoson in hepatocellular carcinoma, MASH, and pancreatic cancer; Phase III progress for Piclidenoson in psoriasis; and new data from compassionate use programs in advanced liver disease. Filings also document regulatory designations like Orphan Drug and Fast Track status, patent grants and notices of allowance, and information about veterinary and human licensing agreements.
CANF’s SEC reports additionally address corporate and financing matters, including public offerings, warrant amendments, reverse stock splits, ADS ratio changes, and shareholder meeting outcomes. Financial statements presented under U.S. GAAP outline revenues from licensing and distribution agreements, research and development expenses for its A3 adenosine receptor-targeted pipeline, and general and administrative costs.
On this page, users can review individual filings and use AI-powered summaries to quickly understand the key points of lengthy documents such as the Form 20-F and detailed Form 6-K exhibits. The platform also makes it easier to track how specific clinical, regulatory, and capital markets events are reflected across multiple filings over time.
Can-Fite BioPharma Ltd. reports that the Canadian Patent Office has issued a notice of allowance for a patent covering its oral drug Namodenoson as an anti-obesity therapy. The patent protects the use of this A3 adenosine receptor agonist to reduce fat mass and body weight in Canada.
The patent stems from data showing Namodenoson increased adiponectin, a hormone that regulates fat production, reduced body weight in an obesity animal model, and produced a 2.3% weight loss over three months in a MASH Phase IIa study. Can-Fite already holds similar Namodenoson obesity patents in the United States and Australia.
Namodenoson is also in Phase III for advanced liver cancer, Phase IIb for MASH, and Phase IIa for pancreatic cancer, and has shown an excellent oral safety profile across multiple clinical studies. Can-Fite highlights that expanding intellectual property into metabolic indications like fat loss may support future development and partnering, within a global obesity treatment market projected to reach $60.5 billion by 2030 with a ~22% CAGR.
Can-Fite BioPharma reports a single compassionate-use case in which its liver drug candidate Namodenoson helped clinically stabilize a patient with advanced decompensated cirrhosis until a compatible donor became available, enabling a successful liver transplantation. Physicians describe this as an encouraging observation but stress that individual cases must be interpreted with caution.
Namodenoson is an orally bioavailable A3 adenosine receptor agonist with anti-inflammatory and anti-fibrotic properties and a favourable safety profile in prior studies. It is being tested in a pivotal Phase III trial for advanced liver cancer, a Phase IIb trial for MASH, and a Phase IIa study in pancreatic cancer. Can-Fite also highlights its broader pipeline, including Piclidenoson for psoriasis and CF602 for erectile dysfunction.
Can-Fite BioPharma Ltd. reports that it received a notice of non-compliance from NYSE American because its audit committee currently has fewer than three independent members following an independent director’s resignation. The company has until the earlier of its next annual shareholder meeting or January 14, 2027 (or, if that meeting is held before July 13, 2026, until July 13, 2026) to regain compliance, and its ADSs continue to trade on NYSE American under the symbol CANF.
To address this, Can-Fite has called a Special General Meeting for March 3, 2026 in Ramat Gan, Israel. Shareholders and ADS holders of record as of February 5, 2026 will vote on electing Ilan Tamir as an external director, with the expectation that he will join the audit committee, helping restore compliance. They will also vote on granting each non-executive director (excluding the executive chair) 16,000 options at an exercise price of NIS 6.767 per ordinary share under the 2023 Share Option Plan and on adopting a renewed compensation policy that updates salary ranges, benefits, equity incentives and a detailed clawback framework for incentive-based pay.
Can-Fite reports 2,618,424 ordinary shares outstanding as of January 26, 2026, each carrying one vote at the meeting, with specific quorum and majority rules, including special approval thresholds for certain pay-related items involving controlling or interested shareholders.
Can-Fite BioPharma Ltd. reports a clinical milestone, completing patient enrollment in its Phase 2a pancreatic cancer study of its liver drug Namodenoson. The multicenter, open-label trial includes patients with advanced pancreatic adenocarcinoma whose disease has progressed after at least one prior therapy and is focused primarily on safety, with additional evaluation of clinical activity and pharmacokinetics.
Patients receive 25 mg oral Namodenoson twice daily in continuous 28‑day cycles, and the company states that Namodenoson has shown a favorable safety profile to date, indicating the primary safety endpoint has been demonstrated so far. Can-Fite expects top-line efficacy data from this study in Q3 2026. Namodenoson, a selective A3 adenosine receptor agonist, holds FDA Orphan Drug Designation for pancreatic cancer and is also in Phase 3 and Phase 2 trials for other liver indications.
Can-Fite Biopharma Ltd. filed a Form 6-K reporting that board member Yaacov Goldman resigned from its Board of Directors and all board committees, effective immediately on January 14, 2026. The company states that Mr. Goldman resigned for personal reasons and that his departure was not due to any disagreement with the company regarding its operations, policies, or practices. The report is also incorporated by reference into Can-Fite’s existing registration statements on Form S-8 and Form F-3, meaning those registration statements now include this update.
Can-Fite BioPharma Ltd. filed a Form 6-K as a foreign private issuer describing a recent corporate update. The company reports that on December 26, 2025 it issued a press release titled “Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction,” highlighting patent protection in Brazil for a sexual dysfunction treatment.
The press release is furnished as Exhibit 99.1 and is incorporated by reference into Can-Fite’s existing shelf and employee benefit plan registration statements on Forms S-8 and F-3, making the patent-related disclosure part of those securities offering documents.
Can-Fite BioPharma Ltd. furnished a report noting that it issued a press release titled “Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change.” The company states that this press release, dated December 23, 2025, is incorporated by reference into its existing Form S-8 and Form F-3 registration statements. The report is signed by Motti Farbstein, who serves as both Chief Executive Officer and Chief Financial Officer.
Can-Fite BioPharma Ltd. changed the terms of an existing warrant package covering 16,666,666 American Depositary Shares. On November 18, 2025, the company agreed with the warrant holder to lower the exercise price on these warrants from $0.60 per ADS to $0.467 per ADS. In exchange, the holder waived certain standstill provisions, which had limited its actions in relation to the company. This adjustment makes it cheaper for the holder to exercise the warrants while releasing the company from the prior standstill constraints.
Can-Fite BioPharma Ltd. submitted a Form 6-K noting that it has furnished a press release as Exhibit 99.1. The press release, dated November 20, 2025, announces that Can-Fite’s CF602 erectile dysfunction treatment has received a notice of patent allowance in Brazil. The first paragraph of this press release is incorporated by reference into several of the company’s existing Form S-8 and Form F-3 registration statements.